%0 Journal Article %T Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series %+ CHU Pontchaillou [Rennes] %+ Centre d'Investigation Clinique [Rennes] (CIC) %+ Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES) %+ Institut de recherche en santé, environnement et travail (Irset) %A Droitcourt, C %A Adamski, Henri %A Polat, A %A Polard, E %A Kerjouan, M %A Arnouat, B %A Le Garrec, M %A Oger, E %A Dupuy, A %A Jouneau, S %< avec comité de lecture %@ 0007-0963 %J British Journal of Dermatology %I Wiley %V 178 %N 3 %P e222-e223 %8 2018-01-30 %D 2018 %R 10.1111/bjd.16016 %M 28963722 %Z Life Sciences [q-bio]/Human health and pathology/DermatologyJournal articles %X The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF. %G English %2 https://univ-rennes.hal.science/hal-01771415/document %2 https://univ-rennes.hal.science/hal-01771415/file/Pirfenidone%20photosensitization%20in%20patients_accepted.pdf %L hal-01771415 %U https://univ-rennes.hal.science/hal-01771415 %~ INSERM %~ UNIV-RENNES1 %~ UNIV-ANGERS %~ IFR140 %~ HL %~ CIC %~ CIC203 %~ IRSET %~ STATS-UR1 %~ IRSET-SMS %~ IRSET-CCII %~ IRSET-TREC %~ IRSET-HIAEC %~ IRSET-SMLF %~ IRSET-ERD %~ IRSET-VCER %~ IRSET-NEED %~ IRSET-TNGC %~ UR1-UFR-SVE %~ UR1-HAL %~ EHESP %~ USPC %~ UR1-SDV %~ REPERES %~ IRSET-1 %~ IRSET-EHESP %~ TEST-UR-CSS %~ UNIV-RENNES %~ IRSET-11 %~ UR1-BIO-SA